Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160037/S026

BD FOX PCR Extraction Tubes; BD Onclarity HPV Assay

Becton Dickinson and Company · Decision date Feb 12, 2026

FDA DECISIONP160037/S026

What did the FDA decide?

FDA records P160037/S026 as a supplement to PMA P160037, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Feb 12, 2026.

FDA approval order statement

an internal building to building transfer of a manufacturing process
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Microbiology
Decision date
Feb 12, 2026
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160037/S026
Regulatory pathway
PMA supplement
Product code
MAQ
Decision code
OK30
Decision date
Feb 12, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: KIT, DNA DETECTION, HUMAN PAPILLOMAVIRUS.

Product code
MAQ
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P160037/S026 received

    Application receipt date recorded by FDA.

  2. P160037/S026 · FDA decision

    30-Day Notice

  3. P160037/S027 · Related supplement

    BD Onclarity HPV Assay Reagent Pack (SKU 444075) and BD COR HPV Extraction Trough (SKU 444074)

Timeline entries are records held by MedtechLedger for P160037. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160037

Product / regulatory recordCompanyPathwayDecision dateSource
Becton Dickinson and CompanyPMA supplementAug 25, 2025FDA
Becton Dickinson and CompanyPMA supplementApr 2, 2026FDA
Becton Dickinson and CompanyPMA supplementApr 2, 2026FDA
Becton Dickinson and CompanyPMA supplementAug 14, 2026FDA
Becton Dickinson and CompanyPMA supplementAug 19, 2026FDA

Explore the linked device profile

Other records with product code MAQ

Product / regulatory recordCompanyPathwayDecision dateSource
cobas HPVP100020/S066
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
cobas HPVP190028/S026
Roche Molecular Systems, Inc.PMA supplementOct 27, 2026FDA
Alinity m HR HPVP230003/S019
Abbott Molecular, Inc.PMA supplementSep 2, 2026FDA
Alinity m HR HPVP230003/S015
Abbott Molecular, Inc.PMA supplementJul 23, 2026FDA
Alinity m HR HPVP230003/S018
Abbott Molecular, Inc.PMA supplementJun 22, 2026FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Becton Dickinson and Company

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
7loveton Cir., Sparks, MD, 21152

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records